Why Novavax Stock Is Volatile This Week
Why Novavax Stock Is Volatile This Week
Novavax Inc (NASDAQ:NVAX) shares dipped 11.2% to $9.60 during Wednesday's session, pulling back following recent strength.
诺瓦瓦克斯医药公司（纳斯达克：NVAX）的股价在周三的交易中下跌了11.2%，跌至9.60美元，此次回调是在近期强劲表现后的走势。
Shares of vaccine makers are volatile this week after the first bird flu death was reported in the U.S. Additionally, a recent CDC report noted an increase in acute respiratory illness activity.
在美国报告了首例禽流感死亡病例后，本周疫苗制造商的股价波动较大。此外，最近的一份CDC报告指出急性呼吸疾病活动有所增加。
What To Know: As a company specializing in vaccine development, Novavax is positioned as a potential player in addressing such outbreaks, particularly given its history of creating vaccines for infectious diseases.
了解一下：作为一家专注于生物-疫苗开发的公司，诺瓦瓦克斯医药有望在应对此类疫情中发挥作用，特别是考虑到其在传染病疫苗开发方面的历史。
Read Also: Apple's 24-Year 70,000% Climb Since iTunes Launch Faces 2025 Test
另见：苹果自iTunes推出以来的24年间增长了70,000%，面临2025年的考验
While traditional bird flu vaccines from Sanofi, CSL Seqirus and GlaxoSmithKline are already stockpiled, they target older H5N1 strains, leaving potential room for innovation and updates.
虽然赛诺菲安万特、CSL Seqirus和葛兰素史克的传统禽流感疫苗已经被储备，但它们针对的是旧的H5N1毒株，这为创新和更新留出了可能的空间。
Novavax, with its proprietary recombinant nanoparticle vaccine technology, could be seen as a contender to develop a next-generation bird flu vaccine if demand grows. The bird flu outbreak, which has devastated poultry farms and raised concerns about viral mutations, could also underscore the need for advanced vaccine platforms.
诺瓦瓦克斯凭借其专有的重组纳米颗粒疫苗科技，可能被视为开发下一代禽流感疫苗的竞争者，尤其是在需求增加的情况下。禽流感疫情已经严重冲击了养禽场，并引发了对病毒突变的担忧，这也突显了先进生物-疫苗平台的必要性。
Investor speculation about potential government funding or contracts to combat the outbreak could likely contribute to volatility in Novavax shares, despite the CDC stating that public risk remains low.
投资者对可能的政府资助或合同以应对疫情的投机，可能会导致诺瓦瓦克斯医药股价的波动，尽管CDC表示公众风险仍然较低。
Read Also: Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
另见：禽流感引发疫苗股票上涨：随着H5N1疫情加剧，值得关注的ETF
How To Buy NVAX Stock
如何购买NVAX股票
By now you're likely curious about how to participate in the market for Novavax – be it to purchase shares, or even attempt to bet against the company.
到现在，你可能对如何参与诺瓦瓦克斯医药的市场感到好奇——无论是购买股票，还是尝试做空这家公司。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
购买股份通常是通过券商账户完成的。你可以在这里找到可能的交易平台列表。许多平台会允许你购买“碎股”，这意味着你可以购买部分股票而不必买入整份股票。例如，一些股票，如伯克希尔哈撒韦或亚马逊，拥有一股可能花费数千美元。然而，如果你只想投资其中的一小部分，券商会允许你这样做。
In the the case of Novavax, which is trading at $9.60 as of publishing time, $100 would buy you 10.41 shares of stock.
在诺瓦瓦克斯医药的情况下，截至出版时，其股价为9.60美元，100美元将可以买到10.41股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果你想对抗一家公司，过程会更复杂。你需要访问一个期权交易平台，或者找一个允许你通过借用股票来'开空'股票的券商。有关做空股票的过程可以在这个资源中找到。否则，如果你的券商允许你交易期权，你可以购买一个看跌期权，或者卖出一个行使价高于当前股价的看涨期权——无论哪种方式，都允许你从股价下跌中获利。
According to data from Benzinga Pro, NVAX has a 52-week high of $23.86 and a 52-week low of $3.53.
根据Benzinga Pro的数据，NVAX的52周最高价为23.86美元，52周最低价为3.53美元。
Image courtesy of Pixabay
图片来自Pixabay
